Siddhartha Mukherjee's third major work of medical nonfiction asks a deceptively simple question: what if you told the story of modern medicine not through diseases or genes, but through the single cell — the actual unit doctors are now learning to extract, edit, and reinject to treat cancer, diabetes, and autoimmune disease? The Song of the Cell won the 2023 PROSE Award for Excellence in Biological and Life Sciences and the 2023 Chautauqua Prize, was named a New York Times Notable Book, and drew a New York Times reviewer who described being "repeatedly dazzled" by the writing — while also flagging its sprawling structure as a real weakness. This review works through what the book actually covers, what critics across major outlets actually said, where the ambition itself becomes the honest complaint, and who's actually going to get the most out of nearly 500 pages on cell biology.
It's worth saying upfront why a book about cell biology, of all things, became a genuine cultural moment rather than staying confined to science-reader circles. Part of it is timing: the book arrived while CAR-T cell therapy and mRNA-based treatments were moving from experimental to mainstream in real hospitals, so readers weren't encountering abstract biology, they were encountering the science behind treatments their own relatives might already be receiving. Part of it is simply Mukherjee's track record — a Pulitzer Prize winner returning to medical nonfiction draws serious critical attention by default. And part of it is the subtitle's promise of a "new human," which reframes what could have been a dry history of biology into a book about where medicine, and human biology itself, might be heading next. That combination of urgency, credibility, and genuine philosophical stakes is why this book generated as much serious critical engagement, award attention, and reader debate as it did.
What The Song of the Cell Actually Is
The Song of the Cell traces the history of humanity's understanding of the cell, from the seventeenth-century moment scientists first realized living tissue was built from discrete, repeating units, through to the present-day therapies built on manipulating individual cells directly — CAR-T cell therapy for cancer, stem cell transplants, in vitro fertilization, and the early edges of synthetic biology. Mukherjee organizes the book into loosely connected sections, each centered on a different organ system or cell type: blood cells and the immune system, neurons and the brain, cardiac cells and the heart, stem cells and regeneration, and the reproductive cells that make new organisms possible in the first place. Rather than a single linear argument, it reads as a series of deep-dive case studies, each one following both the scientific history of a discovery and the human story of a patient whose treatment depended on it.
That patient-centered approach is a Mukherjee signature by now, carried over from his earlier books: each scientific concept gets grounded in a specific person's illness and treatment, which keeps genuinely technical material — cellular signaling pathways, gene editing mechanics, immune cell classification — from reading like a textbook. The book's larger, more provocative claim, hinted at in its subtitle, An Exploration of Medicine and the New Human, is that medicine is entering an era where doctors don't just treat cells indirectly with drugs, but manipulate them directly as building blocks, effectively engineering a "new" version of the patient at the cellular level. That framing is what elevates the book from a history of biology into something closer to a meditation on what medicine, and being human, might mean going forward.
About Siddhartha Mukherjee and Why He Wrote This
Mukherjee is a practicing oncologist and cancer researcher at Columbia University, and his first book, The Emperor of All Maladies: A Biography of Cancer, won the 2011 Pulitzer Prize for General Nonfiction and established him as one of the defining voices in narrative science writing of his generation. His second book, The Gene: An Intimate History, traced the discovery and manipulation of heredity from Gregor Mendel's pea plants through to CRISPR gene-editing technology. The Song of the Cell is widely described as completing an informal trilogy with those two books, moving from disease, to the hereditary code, to the basic living unit that carries out both.
Mukherjee has said the book grew directly out of his clinical work treating cancer patients with cell-based therapies — watching cells themselves, rather than drugs targeting cells from a distance, become the actual treatment. That shift, from prescribing medication to literally engineering living cells and reinjecting them into a patient's body, is happening in real time in oncology wards like his own, and he's been explicit that writing the book was partly an attempt to explain to a general audience just how fundamentally the practice of medicine is changing underneath them, often faster than public understanding of it. As with his earlier books, the writing draws heavily on his own patients and colleagues, several of whom appear as central figures in individual chapters.
How It Compares to The Emperor of All Maladies and The Gene
The three books share a voice and a method — deep historical research paired with vivid patient narrative — but differ meaningfully in focus and, according to many readers, in cohesion. The Emperor of All Maladies has the tightest structure of the three, built around a single disease with a clear historical arc from ancient descriptions of cancer through to modern targeted therapy, which is part of why it won the Pulitzer. The Gene is broader but still organized around one throughline: the discovery and manipulation of heredity. The Song of the Cell is the most ambitious in scope of the three, covering multiple organ systems and cell types rather than one disease or one biological mechanism, and that breadth is exactly where the sprawl critics point to below comes from. If you loved the tight narrative pull of The Emperor of All Maladies, know going in that The Song of the Cell trades some of that focus for range.
What Critics Actually Said
Rather than inventing a verdict, here's what was actually published about it:
“I was repeatedly dazzled — by his pointillist scenes, the enthusiasm of his explanations, the immediacy of his metaphors.”— The New York Times
“Mukherjee takes us through an evolution of human understanding: from the seventeenth-century discovery that humans are made up of cells to our cutting-edge technologies for manipulating and deploying cells for therapeutic purposes.”— The New Yorker
That reception was backed by concrete recognition beyond review copy: the book won the 2023 PROSE Award for Excellence in Biological and Life Sciences and the 2023 Chautauqua Prize, was named a New York Times Notable Book, and appeared on best-of-year lists from The Economist, Oprah Daily, BookPage, Book Riot, and the New York Public Library — an unusually broad sweep across both literary and scientific recognition for the same title.
And the aggregate reader picture, for what it's worth:
Where Real Reviews Pushed Back
The most consistent, specific critique across independent reviews concerns structure and scope, not accuracy or writing quality. The same New York Times review that praised Mukherjee's prose also noted the book's organization can feel sprawling, comparing it to a city that let developers keep building lovely individual houses while doing little to contain the overall sprawl — a vivid way of saying that each chapter dazzles on its own terms while the book as a whole can feel like it's covering too much ground to build toward one destination. Other reviewers have raised a related point: given how much territory the book covers — the brain, the heart, stem cells, the immune system, reproductive cells — there are real, current scientific and ethical debates within cell biology that get only glancing treatment, simply because there isn't room to do justice to all of them in one volume. None of this is a claim that the book is wrong; it's a claim that its ambition occasionally outruns what a single, even very long, book can fully deliver.
On Cell Therapy and the "New Human" the Subtitle Promises
The book's most forward-looking material covers CAR-T cell therapy, stem cell transplantation, and in vitro fertilization — treatments that don't just target cells with drugs from the outside but extract, modify, and reintroduce cells as the therapy itself. Mukherjee walks through this shift largely through his own oncology patients, tracking cases where a patient's own immune cells were removed, genetically reprogrammed to recognize cancer cells, and reinfused, sometimes producing remission in patients who had exhausted every other option. This is where the book's subtitle earns its weight: Mukherjee's argument is that medicine is quietly moving from treating the body as a fixed system to be corrected, to treating it as a system of cells that can be actively re-engineered, and that shift, still in its early stages, is what he means by "the new human."
On the Immune System and the Brain as Cellular Societies
Two of the book's strongest individual sections, according to multiple reviewers, cover the immune system and the brain, both of which Mukherjee frames not as single organs but as societies of specialized cells constantly communicating, cooperating, and sometimes turning on each other. The immune system chapters cover both the history of understanding immune cells and their current therapeutic use, including the autoimmune disease research most directly relevant to Mukherjee's own oncology practice. The brain chapters lean more historical, tracing how neuroscience slowly came to understand neurons as individual cells rather than a continuous, undifferentiated tissue, a discovery that took far longer to establish than most readers realize. Both sections are frequently singled out in reviews as the moments the book's ambition pays off most clearly, even by critics who found the overall structure sprawling.
On the Historical Discovery of the Cell Itself
Before the book gets to modern therapy, it spends substantial time on a slower, stranger story: how long it actually took scientists to accept that all living tissue is built from discrete, self-contained units in the first place. Mukherjee traces this back to seventeenth-century microscopy, when early observers first glimpsed the honeycomb-like structures in cork that gave the cell its name, through centuries of resistance to the idea that something as complex as a human body could really be understood as a society of trillions of individually functioning units rather than one continuous substance. This historical groundwork matters more than it might seem to at first, because it sets up the book's larger argument: every modern cell-based therapy Mukherjee describes later, from bone marrow transplants to CAR-T therapy, depends on a conceptual leap that took science roughly two centuries to fully accept. Reviewers who praised the book's pacing specifically called out this section as proof that Mukherjee can make even slow-moving scientific history feel propulsive, largely by keeping individual scientists and their specific, often flawed, reasoning at the center of the narrative rather than treating discoveries as inevitable.
Key Takeaways
- The book traces cell biology from its seventeenth-century discovery through to today's cell-based therapies like CAR-T treatment and stem cell transplants
- It completes an informal trilogy with The Emperor of All Maladies and The Gene, though all three stand alone and can be read in any order
- It won the 2023 PROSE Award and the 2023 Chautauqua Prize, and was a New York Times Notable Book — real, documented recognition, not just marketing language
- The most consistent criticism is structural: the book's ambitious scope across multiple organ systems can feel sprawling even when individual chapters are excellent
- Mukherjee grounds nearly every scientific concept in a specific patient's story, largely drawn from his own oncology practice at Columbia
Who This Book Is Actually For
Readers who loved The Emperor of All Maladies or The Gene and want more of Mukherjee's patient-centered, historically grounded science writing. It's also a strong fit for anyone with a personal or family connection to cancer treatment, autoimmune disease, or stem cell therapy who wants to understand the science behind modern cell-based medicine without needing a biology degree first.
It also rewards readers who enjoy science writing as literature in its own right, not just as information delivery. Mukherjee's prose gets singled out repeatedly by critics precisely because it treats scientific history with the same narrative attention a good biographer brings to a human subject, which makes the book a reasonable pick even for readers whose primary interest is good nonfiction writing rather than medicine specifically. Book clubs that have previously tackled The Emperor of All Maladies or comparable long-form science nonfiction will find this a natural next selection, particularly given how much material each chapter offers for discussion around ethics, patient autonomy, and where cell-based medicine is headed next.
Who Should Read Something Else Instead
If you want a tightly focused single-subject science book rather than a sprawling, multi-system survey, The Emperor of All Maladies is the more contained and arguably more polished entry point into Mukherjee's work. And if nearly 500 pages of dense biological history sounds like more commitment than you want right now, a shorter, more narrowly scoped popular-science title will likely serve you better than diving straight into this one.
Readers looking specifically for practical, actionable health guidance should also recalibrate expectations. This is a history and a meditation on where medicine is heading, not a patient-facing explainer of how to navigate a specific diagnosis or treatment decision. If you or a family member are actively facing a cell-based therapy decision right now, this book will deepen your understanding of the underlying science, but it isn't a substitute for material written directly for patients making immediate treatment choices, and it shouldn't be read as one.
Pros and Cons
Pros:
- Written by a practicing oncologist with direct clinical experience in the therapies the book describes
- Won the 2023 PROSE Award and 2023 Chautauqua Prize, plus New York Times Notable Book recognition
- Strong 4.25 out of 5 Goodreads rating across thousands of reader ratings
- Vivid, patient-centered storytelling that makes complex cell biology genuinely readable
- Covers cutting-edge, currently-in-use treatments rather than purely historical science
Cons:
- Multiple reviewers, including The New York Times, describe the overall structure as sprawling given its wide scope
- Some current scientific and ethical debates in cell biology get only brief treatment due to the sheer range of topics covered
- At nearly 500 pages, it's a significant time commitment compared to more narrowly focused science titles
Frequently Asked Questions
Do I need to have read The Emperor of All Maladies or The Gene first?
No, The Song of the Cell stands alone. It's often described as completing an informal trilogy with Mukherjee's earlier books, but each one covers a distinct topic -- cancer, genetics, and cellular biology respectively -- and can be read in any order or independently.
What's the actual Goodreads rating for The Song of the Cell?
Roughly 4.25 out of 5 from close to 13,000 ratings on the hardcover edition as of this writing. Check the live number yourself, since it will keep moving.
Did The Song of the Cell actually win any major awards?
Yes -- it won the 2023 PROSE Award for Excellence in Biological and Life Sciences and the 2023 Chautauqua Prize, and was named a New York Times Notable Book and a best book of the year by The Economist, Oprah Daily, BookPage, Book Riot, and the New York Public Library.
What's the most common criticism of this book?
That its scope is almost too ambitious for one volume -- covering the brain, heart, stem cells, the immune system, and more -- which multiple reviewers describe as making the overall structure feel sprawling even while individual chapters dazzle on their own.
Sources & Further Reading
- Goodreads — The Song of the Cell (aggregate rating, reader reviews)
- The New York Times
- The New Yorker
- Kirkus Reviews (starred review)
- PROSE Awards — 2023 winner listing
- Chautauqua Prize — 2023 winner listing
- PositiveLifes.com — free inspirational and life-changing PDF books
On Reading This as a Trilogy Closer Versus a Standalone Book
Because so much coverage frames The Song of the Cell as the third book in an informal trilogy alongside The Emperor of All Maladies and The Gene, it's worth being direct about what that framing does and doesn't mean for a new reader. There's no shared plot, no returning characters, and no requirement to read the earlier books first — each title covers a genuinely separate scientific subject and was written to stand on its own. What connects them is method and voice: the same commitment to grounding hard science in individual patient stories, the same historical patience in tracing how a scientific idea took shape over generations rather than presenting it as a single breakthrough moment. Readers new to Mukherjee entirely can start here without feeling like they've skipped a chapter, though those who do go on to read The Emperor of All Maladies or The Gene afterward often report noticing recurring figures and institutions across all three, a small reward for readers who eventually work through the whole set.
Final Verdict
The Song of the Cell backs up its awards with genuine substance — a PROSE Award, a Chautauqua Prize, and a New York Times review that called the writing dazzling even while flagging its structural sprawl. That sprawl is the one honest reservation worth carrying into this purchase: it's a book that asks for real time and attention across a wide range of organ systems rather than delivering one tight narrative arc. For readers who already trust Mukherjee's voice from his earlier books, or who want the current, unfolding story of cell-based medicine told by someone practicing it, that trade-off is well worth making.
Buy Day rating: 8.8/10